Fig. 3

Predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8 IHC (A) and mRNA (b) expression: high expression (CD8+/CD8A+; in red) and low expression (CD8-/CD8A−; in blue). c, d Kaplan–Meier estimates for progression-free survival; patients were stratified according to PD-L1 IHC (c) and mRNA (d) expression: high expression (Sp142+/CD274+; in red) and low expression (Sp142−/CD274−; in blue). e, f Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8 and PD-L1 IHC (e) and mRNA (f) expression (IHC: CD8+ Sp142+; mRNA: CD8A+ CD274+), and a group with the other patients. g Pathway selected through an enrichment analysis performed on the upregulated genes using Enrichr with the KEGG 2016 database. Heat map of genes significantly differentially expressed between patients with high mRNA CD8 and PD-L1 expressions and the other patients. ^*p < 0.05; ^**p < 0.01; ^***p < 0.001; ^****p < 0.0001; ns not significant